期刊文献+

维持性血液透析患者纠正贫血对逆转左心室肥大的影响 被引量:1

Effects of remedied amenia on left ventricular hypertrophy in maintenance hemodialysis patients
下载PDF
导出
摘要 目的观察维持性血液透析(MHD)患者应用促红细胞生成素(EPO)、左旋卡尼汀纠正贫血的效果及贫血纠正对逆转左心室肥厚(LVH)的影响。方法MHD伴贫血[血红蛋白(Hb)<90g/L]患者40例,每周血透后予EPO(A组)或EPO+左旋卡尼汀(B组)治疗,为期24周,监测血压、左心室重量指数(LVWI)、红细胞压积(Hct)、网织红细胞(RCT)、血清白蛋白和肉碱浓度。结果治疗后两组LVH均明显下降(P<0.05或P<0.01),Hb均明显升高(P<0.05),且B组比A组更明显(P<0.05);白蛋白、肉碱浓度A组略有升高(P>0.05),B组明显升高(P<0.05或P<0.01),且高于A组(P<0.05或P<0.01)。结论EPO+左旋卡尼汀治疗能明显提高MHD患者Hb水平,同时可部分逆转LVH。 Objective To investigate the efficacy of recombinant human erythropoietin(EPO) in combination with L-carnitine on anemia in maintenance hemodialysis patients as well as the effect of remedied anemia on reversing the left ventricular hypertrophy (LVH). Methods Forty patients underwent hemodialysis for at least three months prior to the study(Hb〈90 g/L) were selected and randomly divided into two groups. The patients in group A were treated with EPO, while those in group B with EPO in combination with L-carnitine. All patients received a six-month therapy, wherein the parameters for hematocrit (Hct), reticulocyte (RCT), systolic blood pressure, diastolic blood pressure,albumin,carnitine concentration and left ventricular mass index(LVMI were recorded and studied. Results After the six-month therapy,the Hb in both groups increased markedly with the Hb in group B much higher than that in group A(P〈0. 05 or P〈0. 01). There was no significant increase in ALB or carnitine concentration in group A after the treatment(P〈0.05) but a noticeable drop in LVH(P〈0. 05), which was significantly increased in both ALB and carnitine concentration(P〈0. 05 or P〈0. 01) with a noticeable drop in LVH(P〈0. 05) in group B after the treatment. The ALB and carnitine in group B after the treatment were much higher than those in group A(P〈0. 05 or P〈 0. 01) while LVH in group B was much lower than that in group A(P〈0. 05). Conclusion The therapy of recombinant human EPO in combination with L-carnitine can markedly elevate Hb in MHD patients and LVH could be reversed partly at the same time.
出处 《江苏医药》 CAS CSCD 北大核心 2007年第11期1121-1123,共3页 Jiangsu Medical Journal
关键词 维持性血液透析 贫血 左心室肥厚 Maintenance hemodialysis Anemia Left ventricular hypertrophy
  • 相关文献

参考文献10

  • 1Rayner He, Pisoni RL, Bommer J, et al. Mortality and hospitalization in hemodialysis patients in five European Countries; Results from the Dialysis Outcomes and Practice Patterns Study(DOPPS) [J ]. Nephrol Dial Transplant, 2004, 19 ( 1 ) : 108-120.
  • 2Foley R, levey A, Sarnak M. Clinical epideminology of cardiovascular disease in chronic renal failure[J]. Am J Kidney Dis, 1998,32(Suppl 2) :112-119.
  • 3Levin A, Singer J, Thompson CR, et al. Pravalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention[J]. Am J Kidney Dis, 1996, 27 (3) :347-354.
  • 4Fellner SK, Uang RM, Neumann A, et al. Cardiovascular consequences of correction of the anerrda of renal failure with erythropoietin[J]. Kidney Int, 1993,44(6) : 1309-1315.
  • 5何朝生,梁馨苓,史伟,刘双信,梁永正.不同形式补铁对使用促红细胞生成素治疗肾性贫血疗效的影响[J].广东医学,2001,22(4):312-314. 被引量:18
  • 6唐琦,汪关煜,钱莹,朱萍,沈平雁.肾性贫血时静脉与口服铁剂的疗效比较[J].中国血液净化,2004,3(8):431-434. 被引量:38
  • 7Umberto C, Luciana L. Effects of L-camitine on anemia in aged hemodialysis patients treated with recombinant hu,man erythropoietin:a pilot study[J]. Dialysis Transplant, 1998,27 (8):498-504.
  • 8王福荣,袁志忠,徐洪实,梅长林.左旋肉碱与促红细胞生成素并用治疗尿毒症贫血[J].肾脏病与透析肾移植杂志,1999,8(2):132-134. 被引量:27
  • 9叶朝阳,沈兰贞,梅长林,张翼翔.左旋卡尼汀与红细胞生成素治疗肾性贫血的中期疗效观察[J].第二军医大学学报,2000,21(6):560-562. 被引量:12
  • 10Nationl Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure[J]. Am J Kindney Dis,2000,35(Suppl 2) :S1-S140.

二级参考文献25

  • 1杜金云 袁志忠.重组人红细胞生成素治疗时产生的高血压[J].国外医学生理、病理科学与临床分册,1997,17:378-378.
  • 2[1]Eschbach JW,Egrie JC,Downing MR,et al.Correction of the anemia of end-stage renal disease withrecombinant human erythropoietin.N Engl J Med,1987,316:73
  • 3[2]Anastasslades EG,Howarth DHJ,Shanks D,et al.Monitoring of iron requirements in renal patient on erythropoietin .Nephrol Dial Transplant,1993,8:846
  • 4[3]Levin NW,Lazarus JM,Missensson AR,et al.National cooperative rHu-erythropoietin study in patients with chronic renal failure:an interm report.Am J Kindey Dis,1993,22(Suppl 1):3
  • 5[4]Iain C,Macdougall,Beatriz T,et al.A randomized controlled study of iron supplementation in patients treated with erythropoietin.Kidney Int,1996,50:1694
  • 6[5]Cavill I,Macdougall IC.Erythropoiesis and iron supply in patients treated with erythropoietin.Erythropoiesis,1992,3:50
  • 7[6]David B,Van Wyck MD,Gullio Cavallo MD,et al.Safety and efficaay of iron sucrose in patients sensitive to iron dextran:North American clinical trial.AM J Kindey Dis,2000,36(1):88
  • 8[7]Allen R,Nissensson MD,Robert M,et al.Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients.Am J Kidney Dis,1999,133(3):471
  • 9[1]Parker PA, Izard MW, Maher JF: T heraphy of iron deficiency anemia in paitient on maintenance dialysis. Nephron 1983,23: 229 - 231
  • 10[2]Silverberg DS, Ianina A,Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the anemia of moderate to severe chronic renal failure patients not receiving dialysis.Am J kidney Dis 1996,27:234-238

共引文献88

同被引文献4

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部